Skip to main content

Table 2 Distribution of CYP2D6 genotype, metabolizer phenotype and activity score

From: Tafenoquine treatment of Plasmodium vivax malaria: suggestive evidence that CYP2D6 reduced metabolism is not associated with relapse in the Phase 2b DETECTIVE trial

CYP2D6 genotype CYP2D6 metabolizer phenotypea CYP2D6 activity scoreb All subjects n = 199 N (%) India n = 3 N (%) Peru n = 114 N (%) Thailand n = 82 N (%)
*4/*4 PM 0 1 (0.5) 1 (0.9)
*4/*41 IM 0.5 1 (0.5) 1 (0.9)
*1/*4 IM 1.0 11 (5.5) 8 (7.0) 3 (3.7)
*10/*10 IM 1.0 19 (9.5) 19 (23.2)
*10/*41 IM 1.0 2 (1) 2 (2.4)
*2/*4 IM 1.0 3 (1.5) 3 (2.6)
*41/*41 IM 1.0 2 (1) 2 (2.4)
*1/*10 EM 1.5 15 (7.5) 15 (18.3)
*1/*41 EM 1.5 6 (3) 3 (2.6) 3 (3.7)
*1/*9 EM 1.5 2 (1) 2 (1.8)
*2/*10 EM 1.5 14 (7) 14 (17.1)
*2/*41 EM 1.5 4 (2) 4 (4.9)
*1/*1 EM 2.0 47 (23.6) 35 (30.7) 12 (14.6)
*1/*2 EM 2.0 45 (22.6) 3 (100) 40 (35.1) 2 (2.4)
*2/*2 EM 2.0 27 (13.6) 21 (18.4) 6 (7.3)
  1. aCYP2D6 poor metabolizers (PM), intermediate metabolizers (IM), extensive metabolizers (EM)
  2. bCYP2D6 activity score is the sum of the per-allele scores; a null allele having a score of 0, a deficient allele a score of 0.5 and a normal allele a score of 1 [12]